Bausch & Lomb eyes US besifloxacin launch following panel endorsement
This article was originally published in Scrip
Executive Summary
Bausch & Lomb's novel fluoroquinolone Optura (besifloxacin ophthalmic suspension, 0.6%) should be approved for treating bacterial conjunctivitis, the US FDA's outside experts said on December 5th.